Anakinra Ineffective for Reducing Symptoms of Chronic Fatigue

Share this content:
Anakinra Ineffective for Reducing Symptoms of Chronic Fatigue
Anakinra Ineffective for Reducing Symptoms of Chronic Fatigue

TUESDAY, March 7, 2017 (HealthDay News) -- The anti-inflammatory biologic drug anakinra (Kineret) does not reduce fatigue severity in women with chronic fatigue syndrome, according to a study published online March 7 in the Annals of Internal Medicine.

To test anakinra's potential as a treatment, Megan E. Roerink, M.D., of the Radboud University Medical Centre in Nijmegen, Netherlands, and colleagues randomly assigned 25 women with chronic fatigue syndrome to receive daily 100-mg injections of the drug. Another 25 women received a placebo.

After one month, the researchers saw no meaningful difference between the two groups in fatigue severity. Other symptoms -- including pain, distress, and physical and social functioning -- were not appreciably different, either.

"Peripheral interleukin-1 inhibition using anakinra for four weeks does not result in a clinically significant reduction in fatigue severity in women with chronic fatigue syndrome and severe fatigue," the authors write.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA Approves Admelog for Diabetes

FDA Approves Admelog for Diabetes

First drug approved as a follow-up product based on an abbreviated new process

High-Intensity Treadmill Exercise Feasible in Parkinson's Disease

High-Intensity Treadmill Exercise Feasible in Parkinson's Disease

Mean change in Unified Parkinson's Disease Rating Scale motor score lower for high-intensity exercise

is free, fast, and customized just for you!

Already a member?

Sign In Now »